| Literature DB >> 26938569 |
Tor Paaske Utheim1,2,3, Øygunn Aass Utheim4, Qalb-E-Saleem Khan5, Amer Sehic6.
Abstract
The cornea is critical for normal vision as it allows allowing light transmission to the retina. The corneal epithelium is renewed by limbal epithelial cells (LEC), which are located in the periphery of the cornea, the limbus. Damage or disease involving LEC may lead to various clinical presentations of limbal stem cell deficiency (LSCD). Both severe pain and blindness may result. Transplantation of cultured autologous oral mucosal epithelial cell sheet (CAOMECS) represents the first use of a cultured non-limbal autologous cell type to treat this disease. Among non-limbal cell types, CAOMECS and conjunctival epithelial cells are the only laboratory cultured cell sources that have been explored in humans. Thus far, the expression of p63 is the only predictor of clinical outcome following transplantation to correct LSCD. The optimal culture method and substrate for CAOMECS is not established. The present review focuses on cell culture methods, with particular emphasis on substrates. Most culture protocols for CAOMECS used amniotic membrane as a substrate and included the xenogeneic components fetal bovine serum and murine 3T3 fibroblasts. However, it has been demonstrated that tissue-engineered epithelial cell sheet grafts can be successfully fabricated using temperature-responsive culture surfaces and autologous serum. In the studies using different substrates for culture of CAOMECS, the quantitative expression of p63 was generally poorly reported; thus, more research is warranted with quantification of phenotypic data. Further research is required to develop a culture system for CAOMECS that mimics the natural environment of oral/limbal/corneal epithelial cells without the need for undefined foreign materials such as serum and feeder cells.Entities:
Keywords: cornea; limbal stem cell deficiency; ocular surface disease; oral mucosal epithelial cell sheet; substrates
Year: 2016 PMID: 26938569 PMCID: PMC4810064 DOI: 10.3390/jfb7010005
Source DB: PubMed Journal: J Funct Biomater ISSN: 2079-4983
Figure 1Treatment of LSCD based on various methods using CAOMECS. A biopsy from the mucosa is harvested from the oral cavity (A). The biopsy is cultured in the laboratory on different substrates (B) for 7–28 days (C). A stratified cultured tissue is produced (D) and is transplanted to the diseased eye (E).
Culture of oral mucosal epithelial cells on amniotic membrane.
| Author, Year | Type of Study | Cell Suspension/Explant | Substrate | Air-Lifting | Serum | 3T3 | Culture Medium | Culture Time (Days) | Morphology | Phenotype |
|---|---|---|---|---|---|---|---|---|---|---|
| Shimazaki | Animal | Cell suspension | Denuded AM | Yes | FBS | Yes | SHEM (aprotinin) | 7–10 | Multilayered stratified epithelium; Tight junctions | Expression of K3, ZO-1, and occludin |
| Sekiyama | Cell suspension | Denuded AM | Yes | – | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 7–14 | – | Expression of VEGF and Flt-1; Low expression of PEDF | |
| Sotozono | Clinical | Cell suspension | Denuded AM | Yes | HAS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 8–9 | – | – |
| Sotozono | Clinical | Cell suspension | Denuded AM | Yes | HAS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 8–9 | – | – |
| Gaddipati | Clinical | Explant | Denuded AM | – | – | No | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 9 | 5–6 cell layers; Stratified epithelium | Expression of K3, K12, K19, Ki-67, p75, and PAX6; p63 expression in most of the basal and supra basal cells |
| Sen | Explant | Denuded AM | Yes | FCS | Yes | DMEM:F12 (penicillin, streptomycin, amphotericin, EGF, insulin) | 14 | Stratified epithelium; Desmosomes; Abundant mucin granules | Expression of K3, K4, K13, connexin 43, p63, p75, β1-integrin, CD29, ABCG2, and MUC 1, 5B, 6, 13, 15 and 16 | |
| Satake | Clinical | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM:F12 (gentamycin, streptomycin, penicillin, amphotericin, EGF, insulin) | >14 | Non-keratinized, squamous, polygonal, cells with a low nuclear to cytoplasmatic ratio | – |
| Takeda | Clinical | Cell suspension | Denuded AM | Yes | – | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 14–16 | – | – |
| Chen | Clinical | Cell suspension | Denuded AM | No | FCS | Yes | DMEM:F12(penicillin, streptomycin, insulin, cholera toxin, EGF) | 14–21 | 2–5 cell layers; Elongated cell nuclei | Expression of K3, K4, K13, p63, p75, and ABCG2 |
| Chen | Clinical | Cell suspension | Denuded AM | No | FCS | Yes | SHEM (penicillin, streptomycin, insulin, cholera toxin, EGF) | 14–21 | 5–10 cell layers; Stratified epithelium | Expression of FGF2, K8, VEGF, endostatin, PEDF, and IL-1ra |
| Ma | Clinical | Suspension | Denuded AM | No | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 14–21 | 2–5 cell layers; Elongated cell nuclei | Expression of K3, K13, p63, p75, and ABCG2 |
| Nakamura | Clinical | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 14–21 | 5–6 cell layers; Desmosomes and hemidesmosomes | Expression of K3, K4, and K13 |
| Ang | Clinical | Cell suspension | Denuded AM | Yes | HAS/FBS | Yes | KGM (penicillin, streptomycin, insulin, EGF) | 15–16 | 4–6 cell layers; Cuboidal cells, More flattened cells superficially | Expression of K3, K4, K13, ZO-1, desmoplakin, integrin-α1, laminin 5, and collagen IV |
| Ang | Clinical | Cell suspension | Denuded AM | Yes | HAS/FBS | Yes | KGM (penicillin, streptomycin, insulin, EGF) | 15–16 | 4–6 cell layers; Cuboidal cells, More flattened cells superficially | Expression of K3, K4, K13, ZO-1, desmoplakin, integrin-α1, laminin 5, and collagen IV |
| Inatomi | Clinical | Cell suspension | Denuded AM | Yes | FCS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 15–16 | 5–6 cell layers; Cuboidal cells, several suprabasal cell layers, and flat apical cell layers | Expression of VEGF, FGF, and thrombospondin 1 |
| Inatomi | Clinical | Cell suspension | Denuded AM | Yes | FCS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 15–16 | 5–6 cell layers; Cuboidal cells, several suprabasal cell layers, and flat apical cell layers | Expression of VEGF, FGF, and thrombospondin 1 |
| Inatomi | Clinical | Cell suspension | Denuded AM | Yes | HAS/FCS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 15–16 | 5–6 cell layers; Cuboidal cells, several suprabasal cell layers, and flat apical cell layers | |
| Nakamura | Clinical | Cell suspension | Denuded AM | Yes | HAS | Yes | KGM (penicillin, streptomycin, insulin, cholera toxin, EGF) | 15–16 | – | – |
| Priya | Clinical | Cell suspension | Denuded AM | No | AS | Yes | DMEM:F12 (PI, mouse IgG1/IgG2a, mitomycin C, EGF, insulin, penicillin, streptomycin) | 18–21 | Flat and uniformly distributed epithelial cells | Low expression of p63 (3.0% ± 1.7% of cells); Negative expression of K12 |
| Sharma | Cell suspension | Denuded AM | – | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 21 | 3–5 cell layers; Stratified epithelium | Expression of K3 and β1-integrin; High expression of p63 | |
| Promprasit | Explant | Denuded AM | Yes | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, EGF) | 21 | 2–5 cell layers; Stratified epithelium; Cuboidal cells in basal layer, flat superficial cells | Expression of K3 and connexin 43; High expression of p63 | |
| Nakamura | Animal | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 21 | 3–5 cell layers; Stratified epithelium; | Expression of K3, K4, and K13 |
| Nakamura | Animal | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 21 | 5–6 cell layers; Stratified epithelium; | Expression of K3, K4, and K13 |
| Nakamura | Animal | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF) | 21 | 5–6 cell layers; Stratified epithelium; | Expression of K3, K4, and K13 |
| Kolli | Clinical | Explant | Intact AM | Yes | HAS | No | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF, hydrocortisone, triiodothyronine, adenine) | 21 | 3–7 cell layers, firmly attached to each other; High nucleus to cytoplasm ratio | Expression of K3, ABCG2, and C/EBPδ; High expression of ΔNp63α; Negative for K12 and PAX6 |
| Madhira | Cell suspension | Denuded AM | No | FCS | No | DMEM:F12 (penicillin, streptomycin, amphotericin, gentamycin, insulin, cholera toxin, EGF) | 21–28 | 2–3 cell layers; Stratified epithelium; Gap junctions and desmosomes | Expression of K3, K4, K15, and connexin 43; Negative for K12 and PAX6 | |
| Yokoo | Cell suspension | Denuded AM | Yes | FBS | Yes | DMEM/F12 (penicillin, streptomycin, amphotericin) | 28 | 3–5 cell layers; Stratified epithelium | – |
ABCG2, ATP binding cassette subfamily G member; AM, amniotic membrane; AS, autologous serum; DMEM, Dulbecco’s modified eagle medium; EGF, epidermal growth factor; FBS, fetal bovine serum; FCS, fetal calf serum; FGF2, fibroblast growth factor 2; Flt-1, Fms-like tyrosine kinase 1; HAS, human autologous serum; IgG2a, immunoglobulin G2a; IL-1ra, interleukin 1ra; KGM, keratinocyte growth medium; MUC, mucin; PAX6, paired box 6; PEDF, pigment epithelium derived factor; PI, propidium iodide; SHEM, supplemented hormonal epithelial medium; VEGF, vascular endothelial growth factor; ZO-1, zona occludens protein 1; –, indicates not reported.
Culture of oral mucosal epithelial cells on temperature-responsive surfaces.
| Author, Year | Type of Study | Cell Suspension/Explant | Substrate | Air-Lifting | Serum | 3T3 | Culture Medium | CultureTime (Days) | Morphology | Phenotype |
|---|---|---|---|---|---|---|---|---|---|---|
| Burillon | Clinical | Cell suspension | CellSeed a | No | – | Yes | – | – | Similar characteristics to normal corneal epithelium; Basal membrane | Expression of K3/76, p63, laminin 5, and β1-integrin |
| Soma | Animal | Cell suspension | CellSeed a | – | FBS | Yes | DMEM:F12 (insulin, triiodthyronine, hydrocortisone) | 10–12 | 3–4 cell layers; Stratified epithelium; Cobble stone-like cell morphology | Expression of K14 and p63 |
| Sugiyama | Animal | Cell suspension | CellSeed a | – | FBS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, cholera toxin, EGF, hydrocortisone, triiodothyronine) | 14 | 3–5 cell layers; Stratified epithelium; Cuboidal cells in the basal layer, squamous epithelium on the apical side | Expression of K4, K13, MUC5 |
| Nishida | Clinical | Cell suspension | CellSeed a | No | – | Yes | – | 14 | Multilayered cell sheets; Microvilli, desmosomes, basement membrane | Expression of β1-integrin, K3, and p63 |
| Bardag-Gorce | Animal | Cell suspension | CellSeed a | – | FBS | Yes | – | 14 | Multilayered stratified epithelium | Expression of K4, ΔNp63, TIMP-1, TIMP-3, and connexin 43 |
| Hayashida | Animal | Cell suspension | CellSeed a | – | FBS | Yes | – | 14 | 3–5 cell layers; Stratified epithelium; | Expression of K3, K4, K13, p63, ΔNp63, and β1-integrin |
| Murakami | Cell suspension | CellSeed a | – | HAS | No | DMEM/F12 (penicillin, streptomycin, fungizone, transferrin, EGF, cholera toxin, hydrocortisone, triiodothyronine) | 14 | 3–5 cell layers; Cuboidal basal cells, flattened middle cells, and polygonal flattened superficial cells | Expression of p63 and Ki67 | |
| Oie | Clinical | Cell suspension | CellSeed a | – | HAS | Yes | – | 14–17 | 4–5 cell layers; Small basal cells, flattened middle cells, and polygonal flattened superficial cells | Expression of K1, K3/76, K4, K10, K12, K13, K15, ZO-1, and MUC16; Moderate expression of p63 (30.7% ± 7.6% of cells) |
Culture of oral mucosal epithelial cells on other substrates.
| Author, Year | Type of Study | Cell Suspension/Explant | Substrate | Air-Lifting | Serum | 3T3 | Culture Medium | Culture Time (Days) | Morphology | Phenotype |
|---|---|---|---|---|---|---|---|---|---|---|
| Satake | Clinical | Cell suspension | Fibrin-coated cell culture inserts | Yes | HAS | Yes | DMEM:F12 (penicillin, streptomycin, transferrin, EGF, hydrocortisone, triiodothyronine) | – | 5–6 cell layers; | – |
| Hirayama | Clinical | Cell suspension | Fibrin-coated cell culture inserts | Yes | HAS | Yes | DMEM:F12 (penicillin, streptomycin, insulin, EGF, hydrocortisone) | – | 5–6 cell layers; | – |
| Sheth | Explant | Fibrin gel | – | FCS | No | DMEM:F12 (penicillin, cholera toxin, insulin, EGF, hydrocortisone) | - | Multilayered epithelium; Cobblestone morphology | Expression of K3, K13, and K19; High expression of p63 | |
| Ilmarinen | Cell suspension | Collagen IV-coated cell culture inserts | Yes | No | No | Serum-free oral PCT epithelium medium (EGF) | 13–17 | 4–12 cell layers; Stratified epithelium; Cuboidal basal cells and flat intermediate and superficial cells | Expression of K3/12, K4, K13, Ki67, and p63 | |
| Kanayama | Cell suspension | Culture plate | – | FBS | Yes | DMEM (Supplements not reported) | – | Multilayered cells; Normal epithelial morphology | Expression of FGF2, VEGF, Ang1, and TGF-β1 | |
| Kanayama | Cell suspension | Culture plate | – | FBS | Yes | DMEM (Supplements not reported) | 14 | Multilayered cells | Expression of VEGFr-1 | |
| Hyun | Animal | Cell suspension | Culture plate | – | FBS | Yes | DMEM:F12 (penicillin, streptomycin, gentamycin, amphotericin) | 14 | 2–6 cell layers; Stratified epithelium | Expression of K3, K4, and Ki67; High expression of p63 |
| Krishnan | Explant | Culture plate | – | FBS | – | DMEM:F12 (streptomycin, amphotericin, EGF, insulin, transferrin, selenium, hydrocortisone) | 21 | Multilayered cells; Normal epithelial morphology | Expression of ABCG2, K3, MUC1/4/16, hBD1/2,3; High expression of p63 and ΔNp63 |
ABCG2, ATP binding cassette subfamily G member; Ang1, angiopoietin; DMEM, Dulbecco’s modified eagle medium; EGF, epidermal growth factor; FBS, fetal bovine serum; FCS, fetal calf serum; FGF2, fibroblast growth factor 2; HAS, human autologous serum; hBD, human beta defensing; MUC, mucin; PCT, progenitor cell-targeted; TGF-β1, transforming growth factor beta 1; VEGF, vascular endothelial growth factor; –, indicates not reported.
Expression of p63 in cultured autologous oral mucosal epithelial cell sheet cultivated on different substrates.
| Substrate | Total Number of Studies | Expression of p63 Not Reported | Non-Quantitative Expression of p63 Reported | Quantitative Expression of p63 Reported |
|---|---|---|---|---|
| Amniotic membrane | 24 | 16 studies | 4 studies: p63 expressed; | 1 study: 3.0% ± 1.7% of cells |
| Temperature-responsivecell-culture inserts | 9 | 2 studies | 6 studies: p63 expressed | 1 study: 30.7% ± 7.6% of cells |
| Fibrin-coated culture plate | 2 | 2 studies | – | – |
| Fibrin gel | 1 | – | 1 study: high expression of p63 | – |
| Collagen IV-coated culture plate | 1 | – | 1 study: p63 expressed | – |
| Culture plate | 4 | 2 studies | 2 studies: high expression of p63 | – |
Overall Effect of Different Culture Methods and Substrates for Cultured Autologous Oral Mucosal Epithelial Cell Sheet.
| Substrate/Method | Air-lifting | Animal-derived Nutrient | Use of 3T3 | Serum-free Medium | Viability | Morphology | Phenotype (Expression of p63) |
|---|---|---|---|---|---|---|---|
| Amniotic membrane | 17/24 | 16/24 | 21/24 | 0/24 | >98% (1) | 4.2 cell layers (15) | ++ |
| Temperature-responsive cell-culture inserts | 0/9 | 5/9 | 8/9 | 0/9 | 86%–93% (2) | 4.3 cell layers (6) | ++ |
| Fibrin-coated culture plate | 2/2 | 0/2 | 2/2 | 0/2 | 5–6 cell layers (2) | – | |
| Fibrin gel | 0/1 | 1/1 | 0/1 | 0/1 | – | – | +++ |
| Collagen IV-coated culture plate | 1/1 | 0/3 | 0/1 | 1/1 | – | 4–12 cell layers (1) | + |
| Culture plate | 0/4 | 4/4 | 3/4 | 0/4 | – | 2–6 cell layers (1) | +++ |
Number of studies using different culture parameters is presented in the Table; –, indicates not reported; +, low expression of p63; ++, moderate expression of p63; +++, high expression of p63.